^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BGB-A3055

    i
    Other names: BGB-A3055, BGBA3055, BGB A3055
    Associations

    News

    Trials
    Company:
    BeOne Medicines
    Drug class:
    CCR8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=99, Terminated, BeiGene | N=263 --> 99 | Trial completion date: Mar 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2027 --> Jan 2026; This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the CCR8 program.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    12ms
    BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=263, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    1year
    BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=263, Recruiting, BeiGene | Trial completion date: Feb 2025 --> Mar 2027 | Trial primary completion date: Feb 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    over2years
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=318, Recruiting, BeiGene
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    over2years
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=318, Recruiting, BeiGene | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    over2years
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=318, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • IO biomarker • Metastases
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    PD-L1 expression • CCR8 expression
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    almost3years
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=318, Not yet recruiting, BeiGene
    New P1 trial • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    PD-L1 expression • CCR8 expression
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055